کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
4270172 1610871 2014 10 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
A Comparative Randomized Prospective Study to Evaluate Efficacy and Safety of Combination of Tamsulosin and Tadalafil vs. Tamsulosin or Tadalafil Alone in Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
ترجمه فارسی عنوان
یک مطالعه آینده نگر به صورت تصادفی مقایسه ای به منظور ارزیابی اثربخشی و ایمنی ترکیب تامسولوزین و تادالافیل در مقابل تامسولوزین یا تادالافیل در بیماران مبتلا به علائم دستگاه ادراری پایین به علت هیپرپلازی خوش خیم پروستات
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی اورولوژی
چکیده انگلیسی

IntroductionLower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and erectile dysfunction are common disorders of advancing age.AimTo evaluate the efficacy and safety of tamsulosin and tadalafil in patients with LUTS due to BPH.MethodsIn this prospective randomized study, 133 men complaining of LUTS due to BPH were included. Forty-five patients received tamsulosin 0.4 mg/day alone (Group A), 44 patients received tadalafil 10 mg/day (Group B), and combination therapy (tamsulosin and tadalafil both) was instituted in 44 patients (Group C). After a 2-week medication free run-in period, they were evaluated for International Prostatic Symptom Score (IPSS), International Index of Erectile Function score (IIEF5), quality of life (IPSS QoL), maximum urinary flow rate (Qmax), post-void residual urine (PVR) volume, and safety parameters before and at 3 months of treatment.Main Outcome MeasuresThere were primary (IPSS, IPSS QoL index, Qmax, and PVR) and secondary (erectile function [EF] domain scores from IIEF5) efficacy end points. Safety assessment included laboratory tests and patient's reporting of adverse event.ResultsA significant improvement in IPSS score was observed in all the 3 groups A, B, and C (−50.90%, P < 0.05; −33.50%, P < 0.05; and −53.90%, P < 0.05, respectively). IIEF5 score increased significantly in these three groups (+39.28%, P < 0.05; +45.96%, P < 0.05; and +60.23%, P < 0.05, respectively). A significant increase in Qmax and decrease in PVR were also observed (33.99%, P < 0.05; 29.78%, P < 0.05; and 37.04%, P < 0.05) and (−60.90%, P < 0.05; −49.45%, P < 0.05; and −62.97%, P < 0.05, respectively). The QoL scores improved significantly (−73.35%, P < 0.05; −70.26%, P < 0.05; and −79.65%, P < 0.05, respectively). Side effects were dyspepsia, heartburn, headache, flushing, myalgia, and backache. Adverse effect dropout was 3.7%. No participant experienced any severe or serious adverse events.ConclusionsIn patients with LUTS due to BPH, tamsulosin and tadalafil alone or in combination cause a significant improvement in patients with LUTS. Their EF also improves with these medications. The improvement is better with combination therapy compared with single agent alone. Singh DV, Mete UK, Mandal AK, and Singh SK. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. J Sex Med 2014;11:187–196.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: The Journal of Sexual Medicine - Volume 11, Issue 1, January 2014, Pages 187–196
نویسندگان
, , , ,